Iambic Therapeutics priced its initial public offering of 9,375,000 common shares at $16 per share for $150 million of expected gross proceeds before underwriting discounts and expenses. Trading under IAM began on Nasdaq on…
AstraZeneca entered a strategic discovery and licensing collaboration with insitro to identify causal disease biology and advance therapeutics in metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Insitro receives $40 million upfront and may earn up to…
Late catch from 15 October: Recursion announced a $200 million underwritten follow-on offering, updated human data for REC-4881 and the RBM39 degrader REC-1245, and Sanofi’s option of the first development candidate from their collaboration….
GenScript Biotech conditionally placed 77.126 million new shares at HK$30.50 each, targeting net proceeds of approximately HK$2.327 billion. About 70% is intended for artificial-intelligence-driven drug-discovery capacity and infrastructure, 20% for related research, digital-workflow integration…
Chai Discovery announced a research collaboration under which Bristol Myers Squibb will use Chai’s molecular-folding and generative-design models to support therapeutic-antibody discovery across its portfolio and help build a continuously learning discovery system. The…
The AIntibody consortium published a prospective, blinded benchmark of computational antibody discovery in Nature Biotechnology. Twenty-nine organizations submitted 511 designed or ranked antibodies across three tasks — affinity maturation, HCDR3-cluster ranking and out-of-library CDR…
Aureka Biotechnologies closed a $100 million Series B to expand biological foundation models, closed-loop automated experimentation and antibody-drug discovery. Granite Asia funded the first tranche; an unnamed strategic investor led a later tranche, with…
Bristol Myers Squibb is expanding its NVIDIA collaboration with a second DGX SuperPOD built on eight Vera Rubin NVL72 systems. The infrastructure is intended to make large-scale AI broadly available across BMS research, from…
